One possible treatment for resistant acromegaly (in general) is Sorafenib, an RET inhibitor, which acts by blocking GDNF/AKT serine/threonine kinase 1 survival action through protein kinase AMP-activated catalytic subunit alpha 2 and prevents cell death without changing the RET apoptotic pathway [22,161]. This evidence concerns the gene GDNF and acromegaly.